Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Subscribe To Our Newsletter & Stay Updated